Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for publishing professionals · Tuesday, January 21, 2020 · 507,722,432 Articles · 3+ Million Readers

Recombinant Vaccines Market to Reach $21 Billion by 2026; Increasing Number of Regulatory Approvals to Aid Growth, says Fortune Business Insights™

Key Companies Covered in the Recombinant Vaccines Market Research Report GlaxoSmithKline plc., Merck & Co., Inc, Pfizer Inc, Dynavax Technologies, Sanofi, Serum Institute of India Pvt. Ltd, Novartis AG and other key market players.

/EIN News/ -- Pune, Jan. 13, 2020 (GLOBE NEWSWIRE) -- The global Recombinant Vaccines Market size is projected to reach USD 21.00 billion by the end of 2026. The advancements in molecular genomics have opened up a huge potential for market growth. According to a report by Fortune Business Insights, titled “Recombinant Vaccines Market Size, Share & Industry Analysis, By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus, Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2019-2026,” the market size was USD 8.97 billion in 2018. Driven by increasing number of regulatory approvals, the market will exhibit a CAGR of 11.3% during the forecast period, 2019-2026.


For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/recombinant-vaccines-market-101935


Recombinant vaccines are used for the treatment of several critical diseases. The increasing investment in the research and development of newer vaccines will aid the growth of the market in the coming years. This vaccine is developed with the help of the recombinant DNA technology. The benefits offered by these products have allowed treatment of several diseases. Launch of novel recombinant vaccines, coupled with the high efficacy of recombinant vaccines will add to the growing demand for the product. The immunogenic protein associated with these vaccines have allowed applications across diverse domains. Several critical vaccines such as HBV and hepatitis B vaccines are manufactured through the recombinant DNA technology. The growing adoption of these products will have a direct impact on the growth of the market in the coming years.

The report offers insights into the ongoing recombinant vaccine market trends. The report provides forecast values for the market for the period of 2019-2026. It highlights leading companies in the market and discusses the strategies that these companies have adopted in recent years. The competitive landscape scenario has been discussed in detail. Factual figures have been evaluated through trusted sources. Other forecast values have been gathered through interviews and opinions of experienced market research professionals.

Increasing Number of Regulatory Approvals Will Aid Growth

The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the increasing number of regulatory clearances have made the highest impact on the market in recent years. In December 2019, Merck received approval from the US Food and Drug Administration for a new vaccine. The ERVEBO was the first ever Ebola vaccine. The approval for ERVEBO will encourage several manufacturers. In October 2017, the USFDA approved GlaxoSmithKline’s new vaccine SHINGRIX which is used for the treatment of herpes zoster.  The report highlights the importance of these vaccines on the global market. The report includes a few of the other drug approvals of recent years and gauges their impact on the market.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/recombinant-vaccines-market-101935


North America to Emerge Dominant; Emphasis on Product R&D to Aid Growth

The report offers insights into the ongoing recombinant vaccine market trends across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among these regions, North America is likely to emerge dominant in the coming years. The demand for recombinant vaccines has risen dramatically across this region, due to the efficacy provided by the recombinant vaccines in treating complex viral diseases. As of 2018, the market in North America was worth USD 4.12 billion in 2018 and this value is likely to increase further in the coming years. Besides North America, Europe will witness considerable growth due to lesser adoption of immunization policies in under-developed European countries.


List of the leading companies that are operating in the global Recombinant Vaccines Market are:

  • GlaxoSmithKline plc.
  • Merck & Co., Inc
  • Pfizer Inc
  • Dynavax Technologies
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Novartis AG
  • Other Prominent Players


December 2019:
Merck received USFDA approval for ERVEBO, the first Ebola vaccine. Ervebo is a recombinant viral vaccine that is recommended for the treatment of zaire ebolavirus.

October 2017: USFDA approved GlaxoSmithKline’s new vaccine SHINGRIX which is used for the treatment of herpes zoster.


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/recombinant-vaccines-market-101935


Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • New Product Launch
    • Pipeline Analysis
    • Technological Advancements in the Recombinant Vaccines Market
    • Prevalence of Key Diseases- For Key Countries, 2018
    • Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • Global Recombinant Vaccines Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Type
      • Subunit
      • Live Attenuated
    • Market Analysis, Insights and Forecast – By Route of Administration
      • Parenteral
      • Oral
    • Market Analysis, Insights and Forecast – By Disease Indication
      • Human Papillomavirus
      • Hepatitis B
      • Rotavirus
      • Herpes Zoster
      • Meningococcal B
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospital & Retail Pharmacies
      • Government Suppliers
      • Others
    • Market Analysis, Insights and Forecast – By Geography
      • North America
      • Europe
      • Asia pacific
      • Latin America
      • Middle East & Africa

TOC Continued….!


Request  for Customization: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/recombinant-vaccines-market-101935


Have a Look at Related Reports:

Vaccines Market Size, Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases and Bacterial Diseases), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Region Forecast, 2019-2026

Influenza Vaccine Market Size, Share & Industry Analysis, By Type (Inactivated and Live Attenuated), By Valency (Quadrivalent and Trivalent), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2019-2026

Pediatric Drugs and Vaccines Market Size, Share and Global Trend By Product (Vaccines, Drugs) By Disease Indication (Infectious Disease, Cancer, Allergy And Respiratory, Nervous System Disorders, Cardiovascular Disease, Diabetes, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026

Germany Pneumococcal Vaccines Market Size, Share & Industry Analysis, By Product Type (PCV10, PCV13, and PPSV23), By End User (Hospitals, Clinics, and Others) and Region Forecast, 2019-2026

Veterinary/Animal Vaccines Market Size, Share & Industry Analysis, By Product (Inactivated, Live Attenuated, Recombinant, Others), By Animal (Companion, Livestock), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others) and Regional Forecast, 2019-2026

Human Insulin Market Size, Share & Industry Analysis, By Type (Analogue Insulin, Traditional Human Insulin), By Diabetes Type (Type 1, Type 2), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Regional Forecast, 2019-2026

Injectable Drug Delivery Market Size, Share and Global Trend By Device Type (Conventional Injectable, Pre-filled Syringes, Auto-injectors, Pen-injectors, Others), By Application (Autoimmune Disorders, Diabetes, Pain Management, Aesthetic Treatments, Others), By Route of Administration (Subcutaneous, Intravenous, Intramuscular, Others), By End-User (Hospitals, Home Care Settings, Clinics, Others) and Geography Forecast till 2026

Telemedicine Market Size, Share and Global Trend By Type (Products, Services), By Application (Teleradiology, Telepathology, Teledermatology, Telepsychiatry, Telecardiology, Others), By Modality (Store-and-forward (Asynchronous) , Real-time (Synchronous), Others) and Geography Forecast till 2026

Immunoglobulin Market Size, Share and Industry Analysis By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liqui, Lyophilized), By End User (Hospitals, Clinics, Homecare), and Regional Forecast 2018-2025


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Website: https://www.fortunebusinessinsights.com
LinkedIn | Twitter | Blogs

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release